Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study.

Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T, Takahashi T, Sakemura R, Kojima H, Kohno A, Oba MS, Morita S, Sakamoto J, Emi N.

Int J Clin Oncol. 2018 May 29. doi: 10.1007/s10147-018-1300-9. [Epub ahead of print]

PMID:
29845477
2.

Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs.

Miyao K, Terakura S, Okuno S, Julamanee J, Watanabe K, Hamana H, Kishi H, Sakemura R, Koyama D, Goto T, Nishida T, Murata M, Kiyoi H.

Cancer Immunol Res. 2018 Jun;6(6):733-744. doi: 10.1158/2326-6066.CIR-17-0538. Epub 2018 Apr 13.

PMID:
29653982
3.

Successful Treatment of a Case of Late-onset Colitis after Umbilical Cord Transplantation with Metronidazole: A Case Report and Literature Review.

Sakemura R, Hayakawa H, Iida H, Ito M, Kajiguchi T.

Intern Med. 2017 Dec 1;56(23):3219-3223. doi: 10.2169/internalmedicine.8948-17. Epub 2017 Oct 11. Review.

4.

High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype.

Koyama D, Murata M, Hanajiri R, Okuno S, Kamoshita S, Julamanee J, Takagi E, Hirano D, Miyao K, Sakemura R, Goto T, Hayakawa F, Seto A, Ozawa Y, Miyamura K, Terakura S, Nishida T, Kiyoi H.

PLoS One. 2017 Sep 25;12(9):e0185213. doi: 10.1371/journal.pone.0185213. eCollection 2017.

5.

Interdigitating dendritic cell sarcoma successfully treated with ABVD therapy in which serum CEA levels correlated with disease activity.

Sakemura R, Hiraga J, Kitagawa S, Ito M, Kajiguchi T, Mizuno S.

Rinsho Ketsueki. 2017;58(4):292-297. doi: 10.11406/rinketsu.58.292. Japanese.

PMID:
28484155
6.

Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study.

Yokohata E, Kuwatsuka Y, Ohashi H, Terakura S, Kawashima N, Seto A, Kurahashi S, Ozawa Y, Goto T, Imahashi N, Nishida T, Miyao K, Sakemura R, Kato T, Sawa M, Kohno A, Sao H, Iida H, Kiyoi H, Naoe T, Miyamura K, Murata M.

Bone Marrow Transplant. 2017 Apr;52(4):612-614. doi: 10.1038/bmt.2016.323. Epub 2017 Jan 9. No abstract available.

PMID:
28067879
7.

The Efficacy of an Oral Elemental Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Morishita T, Tsushita N, Imai K, Sakai T, Miyao K, Sakemura R, Kato T, Niimi K, Ono Y, Sawa M.

Intern Med. 2016;55(24):3561-3569. Epub 2016 Dec 15.

8.

A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia.

Miyao K, Sawa M, Kurata M, Suzuki R, Sakemura R, Sakai T, Kato T, Sahashi S, Tsushita N, Ozawa Y, Tsuzuki M, Kohno A, Adachi T, Watanabe K, Ohbayashi K, Inagaki Y, Atsuta Y, Emi N.

Int J Hematol. 2017 Jan;105(1):79-86. doi: 10.1007/s12185-016-2095-y. Epub 2016 Sep 30.

PMID:
27696283
9.

Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.

Goto T, Nishida T, Takagi E, Miyao K, Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura S, Murata M, Kiyoi H.

J Immunother. 2016 Oct;39(8):306-15. doi: 10.1097/CJI.0000000000000136.

PMID:
27548033
10.

A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.

Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, Koyama D, Goto T, Hanajiri R, Nishida T, Murata M, Kiyoi H.

Cancer Immunol Res. 2016 Aug;4(8):658-68. doi: 10.1158/2326-6066.CIR-16-0043. Epub 2016 Jun 21.

11.

Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.

Hanajiri R, Murata M, Sugimoto K, Murase M, Sakemura R, Goto T, Watanabe K, Imahashi N, Terakura S, Ohashi H, Akatsuka Y, Kurahashi S, Miyamura K, Kiyoi H, Nishida T, Naoe T.

Bone Marrow Transplant. 2015 Sep;50(9):1187-94. doi: 10.1038/bmt.2015.119. Epub 2015 Jun 1.

PMID:
26030050
12.

Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse.

Imahashi N, Ohashi H, Terakura S, Miyao K, Sakemura R, Kato T, Sawa M, Yokohata E, Kurahashi S, Ozawa Y, Nishida T, Kiyoi H, Watamoto K, Kohno A, Kasai M, Kato C, Iida H, Naoe T, Miyamura K, Murata M; Nagoya Blood and Marrow Transplantation Group.

Ann Hematol. 2015 Jul;94(7):1139-48. doi: 10.1007/s00277-015-2312-4. Epub 2015 Feb 15.

PMID:
25680895
13.

Simple and efficient generation of virus-specific T cells for adoptive therapy using anti-4-1BB antibody.

Imahashi N, Nishida T, Goto T, Terakura S, Watanabe K, Hanajiri R, Sakemura R, Imai M, Kiyoi H, Naoe T, Murata M.

J Immunother. 2015 Feb-Mar;38(2):62-70. doi: 10.1097/CJI.0000000000000069.

PMID:
25658615
14.

Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.

Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M.

J Immunol. 2015 Feb 1;194(3):911-20. doi: 10.4049/jimmunol.1402346. Epub 2014 Dec 17.

15.

Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.

Miyao K, Sakemura R, Imai K, Sakai T, Tsushita N, Kato T, Niimi K, Ono Y, Sawa M.

Int J Hematol. 2014 Aug;100(2):152-8. doi: 10.1007/s12185-014-1608-9. Epub 2014 Jun 20.

PMID:
24947495
16.

Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.

Miyao K, Sakemura R, Sakai T, Tsushita N, Kato T, Niimi K, Ono Y, Sawa M.

Ann Hematol. 2014 Mar;93(3):529-30. doi: 10.1007/s00277-013-1835-9. Epub 2013 Jul 3. No abstract available.

PMID:
23820941
17.

Successful immunosuppressive and iron chelation therapy for a severe aplastic anemia patient undergoing hemodialysis due to chronic renal failure.

Hiraga J, Sakemura R, Yamashita H, Suzuki T, Kitagawa S, Takakuwa Y, Mizuno S.

Int J Hematol. 2011 Apr;93(4):555-557. doi: 10.1007/s12185-011-0816-9. Epub 2011 Mar 23. No abstract available.

PMID:
21431347
18.

Role of PET/CT screening in detecting a second primary carcinoma in patients with malignant lymphoma.

Sakemura R, Hiraga J, Okuda T, Mizuno S.

Ann Hematol. 2011 Dec;90(12):1485-6. doi: 10.1007/s00277-011-1200-9. Epub 2011 Mar 1. No abstract available.

PMID:
21360107
19.

Nuclear swelling occurs during premature senescence mediated by MAP kinases in normal human fibroblasts.

Kobayashi Y, Sakemura R, Kumagai A, Sumikawa E, Fujii M, Ayusawa D.

Biosci Biotechnol Biochem. 2008 Apr;72(4):1122-5. Epub 2008 Apr 7.

20.

G-protein gamma subunit GNG11 strongly regulates cellular senescence.

Hossain MN, Sakemura R, Fujii M, Ayusawa D.

Biochem Biophys Res Commun. 2006 Dec 22;351(3):645-50. Epub 2006 Oct 30.

PMID:
17092487
21.

Prolonged unbalanced growth induces cellular senescence markers linked with mechano transduction in normal and tumor cells.

Sumikawa E, Matsumoto Y, Sakemura R, Fujii M, Ayusawa D.

Biochem Biophys Res Commun. 2005 Sep 23;335(2):558-65.

PMID:
16083852

Supplemental Content

Loading ...
Support Center